Skip to content
Assyro AI
eCTD 4.0 Vendor Landscape in November 2026
ectd 4.0 vendors
ectd v4.0 readiness
ectd 4.0 software

eCTD 4.0 Vendor Landscape in November 2026

Analysis

Compare official eCTD 4.0 vendor positioning in 2026 and review technical changes, authority status, and migration considerations.

Assyro Team
15 min read

Quick Answer

eCTD v4.0 rollout remains authority-specific. FDA officially supports certain new eCTD v4.0 submissions, while other regions continue phased pilots or staged adoption. Vendor claims about "readiness" should be tested against the exact authority, submission type, and production evidence you need.

Key Takeaways

  • eCTD v4.0 is based on HL7 v3 RPS, not FHIR.
  • FDA has published official support for certain new eCTD v4.0 submissions; other authority timelines should be confirmed directly from current primary sources.
  • Vendor claims about pilots, accepted submissions, and authority support should be checked against current official or vendor-primary documentation.
  • Architecture still matters, but buyers should prioritize demonstrable support over marketing language.
  • The eCTD 4.0 transition is no longer theoretical. FDA is already supporting certain new eCTD v4.0 submissions, and multiple other authorities are pursuing staged rollouts, pilots, or local implementation plans.
  • For a detailed look at the technical changes from v3.2.2 to v4.0, see our eCTD v4.0 migration guide.
  • This article focuses on what can be supported directly from authority pages and official vendor materials: the technical shift in the standard, the current public implementation picture, and the questions buyers should ask vendors.
  • In this article, you'll learn:
  • What eCTD v4.0 changes technically (HL7 RPS, metadata, controlled vocabularies)
  • The current implementation picture by region using primary sources only
  • How each major vendor's architecture maps to 4.0 requirements
  • Why the 3.2.2-to-4.0 migration is not a simple upgrade for legacy platforms
  • What to prioritize when evaluating eCTD 4.0 software

What Changes Technically in eCTD v4.0

Definition

eCTD v4.0 is the next-generation electronic Common Technical Document specification, developed under ICH M8, that replaces the XML DTD backbone of v3.2.2 with a messaging architecture based on HL7 Regulated Product Submission (RPS). It introduces metadata-driven content management, controlled vocabularies, and a unified XML message model.

Before evaluating vendors, you need to understand what is actually changing. eCTD v4.0 is not a minor version bump. It changes how regulatory submissions are structured, transmitted, and processed.

From XML Backbone to HL7 RPS

eCTD v3.2.2 uses a directory-based structure with an XML DTD backbone. Submissions are organized as sequential "sequences," each with its own XML index pointing to documents in a folder hierarchy. The Table of Contents (TOC) is rigid and fixed by the specification.

eCTD v4.0 replaces this with an HL7 Regulated Product Submission (RPS) message model rather than the classic v3.2.2 backbone-and-folder approach.

“
Clarification: eCTD v4.0 is based on HL7 v3 RPS, not HL7 FHIR.

Key Technical Differences

Comparison table with columns Dimension, eCTD v3.2.2, eCTD v4.0
DimensioneCTD v3.2.2eCTD v4.0
Message basisXML DTD backboneHL7 v3 RPS R-MIM schema
Message countMultiple sequential XML indicesSingle unified XML message
TOC structureFixed hierarchy defined in specificationDynamic, managed via code lists
Content referencingLeaf elements in folder directoriesContext groups with metadata
Vocabulary managementStatic index listsGenericode-formatted, continuously updatable
Document lifecycleReplace/append/delete per leafOne-to-many replacements via context and priority metadata
Module 1 integrationRegion-specific DTDs, separate filesIntegrated into single RPS message with regional IGs
OrderingImplied by file/folder structureExplicit priority attributes in XML

Metadata and Controlled Vocabularies

eCTD v4.0 introduces a metadata-driven architecture that differs materially from v3.2.2's file-and-folder approach:

  • Context groups assign every document a coded position in the TOC hierarchy (e.g., a Module 3 quality report receives a context group like "3QC").
  • Keywords are controlled codes attached to submissions, capturing attributes such as application type, product classification, or therapeutic area.
  • Priority numbers determine sort order within sections, since XML elements do not inherently preserve sequence.
  • Controlled vocabularies are published as Genericode files by ICH and regional agencies (FDA, EMA, PMDA), and can be updated independently of the core specification.

This is a significant change. In v3.2.2, the TOC structure is largely fixed. In v4.0, new content categories can be handled through controlled vocabulary updates rather than only through broader specification changes. Buyers should therefore confirm how each product handles dynamic TOC resolution, vocabulary versioning, and metadata validation.

Forward Compatibility with v3.2.2

The standard includes forward-compatibility concepts, but a production transition also needs vendor implementation and acceptance by the receiving authority. FDA currently places continuation of existing v3.2.2 applications in a future implementation phase. A vendor conversion demonstration therefore does not authorize an existing FDA application to switch formats. Keep the application’s supported lifecycle path in the operating plan until the relevant authority permits the transition.

FDA eCTD v4.0 implementation status - checked October 5, 2026

eCTD v4.0 Implementation Picture by Region

The rollout is staggered, and not every authority has published the same level of detail.

Comparison table with columns Authority / application context, Current source position, Source and revision checked October 5, 2026
Authority / application contextCurrent source positionSource and revision checked October 5, 2026
FDA CDER/CBER - new applicationsAccepts new v4.0 applications from September 16, 2024; existing-v3.2.2 forward compatibility remains future workFDA implementation page; no revision date displayed
EMA - new CAP MAAsOptional since December 22, 2025; strongly recommended Q1 2027 and mandatory Q1 2028 in the published planEMA update, July 8, 2026
EMA - existing CAP lifecycleForward compatibility remains subject to pilots, technical readiness and further assessmentEMA update, July 8, 2026; do not treat pilot access as general production acceptance
PMDA or another authorityConfirm the current application-specific implementation before choosing a format or transitionNo cross-authority acceptance inferred from FDA or EMA

What This Means in Practice

If you submit to FDA, use FDA's published scope carefully. FDA states support for certain new applications in eCTD v4.0 and notes important current limitations, including forward-compatibility constraints.

For EMA, distinguish the new-CAP-MAA optional-use route from forward-compatibility pilots for existing lifecycle content. The July 8, 2026 update changes the planning dates from older vendor posts; use the authority update for eligibility and timing. For PMDA or another authority, confirm the applicable procedure directly.

If you submit globally, build your plan around the earliest authority that truly applies to your product and submission type, not the most aggressive industry forecast.

Vendor Readiness Assessment

Read the matrix as an evidence register checked October 5, 2026. A product page describes vendor scope; it does not prove your quoted build, license or receiving authority has accepted your intended production workflow. Product pages without a displayed revision are labeled accordingly.

Use the product-and-edition quote comparison to keep authority readiness separate from license and module scope.

Readiness Comparison Matrix

Comparison table with columns Vendor / product, Evidence and version/date, What the evidence establishes, Still required for your purchase
Vendor / productEvidence and version/dateWhat the evidence establishesStill required for your purchase
AssyroAuthoring and validation product scope, checked October 5, 2026FDA v4.0 is live; v3.2.2 is unsupported. EMA is on the roadmapDemonstrate your exact eligible output; do not infer EU support or existing-v3.2.2 continuation
Veeva / RIM and PublishingReadiness article, December 22, 2025Vendor explains its RIM approach to v4.0; historical timing in that post is not current authority guidanceExact deployed release, regional configuration and production evidence; use current EMA dates above
LORENZ / docuBridgeFIVE 24.2 release notes, release-specific evidenceVendor documents forward-compatibility toolingQuoted edition/build and applicable authority permission; technical conversion is not general FDA eligibility
EXTEDO / EXTEDOpulse PublishingProduct page, no revision date displayedVendor lists eCTD v3/v4 workflows and transition toolingLicensed modules, target regional configuration and acceptance evidence
Ennov / DossierProduct page, no revision date displayedVendor lists eCTD 3.2.2 and 4.0 among supported formatsQuoted release, regional templates and production versus pilot scope
Certara / GlobalSubmit PUBLISHProduct page, no revision date displayedVendor describes publishing and points to eCTD4 adoption resourcesVersioned release documentation and authority-specific production scope; a webinar is not an acceptance record

Vendor-by-Vendor Analysis

Assyro AI: Validation-First Positioning

Assyro is positioned as an AI-native compliance platform rather than a traditional legacy publishing suite.

Key capabilities:

  • Validation-first workflow support
  • Cloud-native deployment

FDA eCTD v4.0 is live. eCTD v3.2.2 is not supported, and EMA is on the roadmap. Confirm the authority and accepted format for every other required workflow separately.

Why it matters for 4.0: Buyers evaluating Assyro should ask for concrete evidence of the exact v4.0 workflows they need, not just general positioning around modern architecture.

Learn more at assyro.com.

Veeva Vault RIM: Unified RIM Positioning

Veeva Vault RIM is positioned as an end-to-end regulatory suite covering submission planning, authoring, publishing, and lifecycle management.

eCTD 4.0 status: Veeva publicly discusses eCTD 4.0 readiness within its unified RIM architecture.

Considerations:

  • Buyers using Vault RIM should evaluate how current v4.0 support fits into the broader platform workflow.
  • Veeva's enterprise sales cycle and implementation model may not suit every organization.
  • Buyers should request direct evidence for the exact authorities and submission types they care about.
  • The platform is cloud-native, which aligns well with modern deployment expectations.

Risk factor: Evaluate actual product support, not general roadmap language.

LORENZ docuBridge: Established Publishing Platform

LORENZ docuBridge is an established eCTD publishing tool.

eCTD 4.0 status: LORENZ publicly documents current eCTD 4.0 support in product materials.

Considerations:

docuBridge FIVE 24.2 release notes describe forward-compatibility tooling. Treat that as a product capability claim and separately confirm whether the receiving authority permits the intended transition.

  • LORENZ publicly documents a recurring release cadence for the product.

Identify the exact docuBridge edition, deployment and concurrent-user model in the proposal; do not infer them from a product-family name.

Risk factor: Confirm the exact forward-compatibility and workflow behavior you need using a real dossier or pilot package.

Extedo (EXTEDOpulse / eCTDmanager): Multi-Region Publishing Suite

Extedo positions its products around regulatory portfolio management and multi-region submission support.

eCTD 4.0 status: Extedo publicly documents support for both eCTD v3 and v4 product workflows.

Considerations:

  • Vendor materials describe support across multiple regions.
  • Submission readiness assessments are available as a service offering.
  • Cloud and on-premise deployment options.

Risk factor: Evaluate the actual migration and validation workflow rather than relying on broad marketing descriptions.

Ennov: Dossier and Publishing Suite

Ennov publicly positions its dossier and publishing products around eCTD v4.0 support.

Considerations:

  • Ennov materials describe support for CTD, eCTD (v3 and v4), NeeS, vNeeS, and eCopy formats.
  • Ennov positions its products for both cloud and on-premise deployment.

Risk factor: Ask Ennov to distinguish clearly between pilot evidence, accepted production use, and roadmap commitments.

Certara GlobalSubmit: Publishing and Validation Positioning

Certara's approach to eCTD 4.0 includes public messaging around both sponsor-side publishing and authority-facing partnerships.

The GlobalSubmit PUBLISH page describes publishing and validation features and links resources on eCTD v4.0 adoption. Ask for versioned release documentation and authority-specific production evidence before recording your required v4.0 workflow as supported.

Considerations:

  • Vendor materials describe cloud deployment and multi-region support.
  • Live validation and automated hyperlink creation features.

Risk factor: Ask for authority-specific production evidence rather than broad geographic claims.

The Legacy Architecture Problem

This is the core issue that many vendor comparison articles blur: eCTD v3.2.2 and eCTD v4.0 are not identical operating models.

What v3.2.2 Software Was Built To Do

  • Parse and generate XML DTD backbone files
  • Manage documents in fixed folder hierarchies
  • Handle sequential submission numbering
  • Validate against static rule sets tied to folder structure
  • Generate leaf elements with lifecycle operations (new, replace, append, delete)

What v4.0 Software Must Do

  • Generate and validate HL7 v3 RPS XML messages
  • Manage metadata-driven content with context groups and keywords
  • Resolve dynamic Table of Contents from Genericode vocabulary files
  • Support one-to-many document replacement via metadata, not folder operations
  • Handle priority-based ordering within XML
  • Validate against continuously updatable vocabulary sets published by ICH and regional agencies

Support the required lifecycle operations and, where the authority permits it, forward-compatible continuation from v3.2.2 history

These are materially different requirements. Buyers should therefore test how each product actually handles metadata, controlled vocabularies, and forward compatibility in the workflow they will use.

Why This Matters to You

If your vendor treats v4.0 as an export format rather than a native operating model:

  1. Vocabulary updates may lag. When ICH or a regional agency publishes updated Genericode files, your software needs a clear update path.
  2. Metadata validation may be shallow. Schema validation alone does not prove the metadata model is being used well.
  3. Lifecycle handling may be fragile. v4.0 relies more heavily on metadata relationships than classic folder logic.
  4. Future v4.x updates may expose weak implementations. Extensibility is a strength of v4.0, but only if the product can keep pace.

What to Evaluate When Choosing an eCTD 4.0 Vendor

1. Architecture Origin

Ask: How does the platform currently handle the v4.0 message model, metadata, and controlled vocabularies?

Architecture matters because v4.0 relies more heavily on metadata, vocabulary management, and forward compatibility than v3.2.2.

2. Vocabulary Management

Ask: How does the platform handle Genericode vocabulary updates?

In v4.0, ICH and regional agencies publish controlled vocabulary updates independently of the core specification. Ask the vendor how those updates are applied in practice.

3. Pilot and Production Track Record

Ask: Has the vendor completed successful v4.0 work for your target agencies, and what kind of evidence can they show?

Distinguish clearly between pilot submissions, accepted production use, and general roadmap statements.

Use the planning and acceptance-record approach in the eCTD proof-of-concept guide to separate claims from observed results. Its downloadable fixture targets v3.2.2; a v4.0 evaluation requires separate version-specific inputs and expected results.

4. Forward Compatibility

Ask: How does the platform handle v3.2.2-to-v4.0 lifecycle continuation?

First establish whether the receiving authority permits your existing application to transition. If it does, test the vendor’s operation with the required history. If it does not, assess continued support for the current format separately from future conversion tooling.

5. Multi-Authority Support

Ask: Can the platform produce v4.0 submissions for all your target agencies from a single workspace?

Regional Module 1 Implementation Guides differ between FDA, EMA, PMDA, Health Canada, and others. Ask the vendor how those differences are implemented in the product you will actually use.

6. Validation Depth

Ask: Does the platform validate only XML schema compliance, or does it also provide broader review support?

Schema validation confirms that the XML message is structurally correct. Broader regulatory review checks whether the submission content aligns with agency-specific rules. For a capability comparison, see our eCTD validation software guide.

7. Total Cost of Transition

Ask: What is the full cost of moving to v4.0 with this vendor?

Include software licensing, implementation, training, data migration, validation (per 21 CFR Part 11 / Annex 11), and ongoing maintenance. Some vendors bundle v4.0 in existing subscriptions. Others charge for upgrades, migration services, or additional modules.

The eCTD implementation plan makes source preparation, configuration and acceptance dependencies visible before cutover.

Migration Considerations for Regulatory Teams

Start With Japan (If Applicable)

If your organization submits to PMDA, confirm the current production requirements directly with PMDA and your vendor before setting your internal timeline.

Plan for Dual-Format Operations

The staggered regional timelines mean many organizations may need to operate in both v3.2.2 and v4.0 for a period of time. Your vendor should explain clearly how dual-format support works in practice.

Validate Your Vendor's Output Against Agency Tools

Do not rely solely on your vendor's built-in validator. Use current authority documentation and any available authority-side validation tools or criteria when testing production readiness.

Budget for Training

eCTD v4.0 introduces concepts (context groups, keywords, priority ordering, Genericode vocabularies) that are unfamiliar to teams who have worked exclusively with v3.2.2. Training is not optional. Budget for it explicitly and plan for hands-on practice with test submissions before your first production v4.0 filing.

Assess Your Vendor's Long-Term Viability

Evaluate how each vendor handles specification updates, vocabulary changes, and authority-specific implementation work over time.

The Bottom Line

The eCTD v4.0 transition requires organizations to evaluate software architecture and product evidence carefully. Some vendors already publish concrete support statements and product materials. Others still communicate more cautiously or at a higher level.

For organizations evaluating eCTD 4.0 readiness in 2026, the decision framework is straightforward:

  1. Identify the earliest authority requirement that actually applies to you.
  2. Verify your vendor has demonstrated v4.0 output to your target agencies.
  3. Test the workflow, not just the marketing. Can the platform handle dynamic vocabularies, context groups, and lifecycle changes in practice?
  4. Evaluate total migration cost, including dual-format operations during the transition period.
  5. Choose a platform based on evidence, not generalized readiness language.

The practical takeaway is to treat eCTD v4.0 as both a standards change and a workflow change, not just a naming update in vendor materials.

Frequently Asked Questions

It depends on the region and submission type. FDA has published support dates for certain new eCTD v4.0 submissions. For EMA, PMDA, and other authorities, confirm the latest production status and any mandatory timing directly from current authority sources.

References

EMA eCTD v4.0 implementation update - July 8, 2026

LORENZ docuBridge FIVE 24.2 release notes

EXTEDOpulse Submission Publishing product scope

Ennov Dossier product scope

About the author

Assyro Team

Expert regulatory operations consultants helping pharmaceutical companies navigate complex compliance challenges.

Related articles

Demos available this week